Andrew J. Stephenson M.D.

Dr. Andrew J. Stephenson M.D., MBA, FACS, FRCS(C) is an internationally recognized urologist, robotic surgeon and researcher. Before joining Associated Medical Professionals of NY, he served as Director of Urologic Oncology at Rush University Medical Center, Director of the Center of Urologic Oncology at Cleveland Clinic’s Glickman Urological and Kidney Institute and a staff member of the Taussig Cancer Institute. His clinical and research focus is on the treatment of patients with cancers of prostate, bladder and testis. He has published over 125 articles in peer-reviewed journals since 2002 on issues related to prostate, bladder and testis cancer, many of which have received international mainstream media attention. He has been invited to speak on these subjects at major international medical conferences.

Dr. Stephenson is board-certified in urology by the American Board of Urology and the Royal College of Physicians and Surgeons of Canada. He has received several awards from organizations such as the Prostate Cancer Foundation, American Society of Clinical Oncology and Society of Urologic Oncology. He is listed as one of the Best Doctors in America. He received the Urology Teacher of the Year award while at Rush University and Cleveland Clinic.

Dr. Stephenson has received grant support for prostate cancer research from the Robert Wood Johnson Foundation. His research focus is on the development of prognostic statistical models called nomograms. These prognostic models provide accurate predictions of treatment outcome for prostate cancer and are widely used for patient counseling. He is on the editorial board for several urology journals, including Urology, and is an ad hoc reviewer for Journal of the National Cancer Institute, Journal of Clinical Oncology and Journal of Urology.

For patients with prostate cancer, Dr. Stephenson performs both nerve-sparing robotic prostatectomy using latest state-of-art approaches. The decision to perform either robotic or open prostatectomy is tailored to the specifics of each patient’s cancer and preferences. For patients with bladder cancer, Dr. Stephenson also performs robotic nerve-sparing radical cystectomy and orthotopic urinary diversion (neobladder or Studer) for both men and women. He is highly skilled on minimally invasive robotic approaches for kidney tumors and advanced kidney cancers. For select patients with testicular cancer, Dr. Stephenson performs robotic nerve-sparing lymph node dissection. He also has vast experience in minimally invasive treatments for BPH and voiding dysfunction. He has also been a pioneer in the development of biomarkers and image-guided diagnostic approaches for prostate cancer diagnosis and treatment.